<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940078</url>
  </required_header>
  <id_info>
    <org_study_id>NN9838-4614</org_study_id>
    <secondary_id>U1111-1250-7789</secondary_id>
    <nct_id>NCT04940078</nct_id>
  </id_info>
  <brief_title>A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity</brief_title>
  <official_title>Investigation of Pharmacokinetics Following Co-administration of Cagrilintide (NNC0174-0833) and Semaglutide Versus Separate Injections in Subjects With Overweight or Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare two different ways of giving cagrilintide and semaglutide for&#xD;
      treating overweight and obesity. The medicines will either be given together in 1 injection&#xD;
      or as 2 separate injections.&#xD;
&#xD;
      The aim of the study is to find out how the different ways of injection affect the level of&#xD;
      the medicines in the blood.&#xD;
&#xD;
      For the first 14 weeks of the study, participants will get cagrilintide and semaglutide as 2&#xD;
      separate injections. Then participants will either switch to getting the medicines as a&#xD;
      combined injection or continue to get the separate injections for 8 weeks. Which treatment&#xD;
      participants get after the first 14 weeks is decided by chance.&#xD;
&#xD;
      Participants will get the study medicines once a week for 22 weeks. A study nurse at the&#xD;
      clinic will inject the medicines with a thin needle in participants stomach area.&#xD;
&#xD;
      The study will last for about 8 months.Participants will have 28 clinic visits with the study&#xD;
      staff. For 4 of these visits, participants will stay in the clinic for 5 nights.&#xD;
&#xD;
      Participants will have blood drawn at 21 visits. Participants will have clinical assessments&#xD;
      and participants will be asked about their health, medical history and habits including&#xD;
      mental health questionnaires.&#xD;
&#xD;
      For women: Participants must not be able to become pregnant if they wish to participate in&#xD;
      this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">February 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The trial consists of a Part A with multiple weekly dosings at site and a Part B with a single dose (SD) part of the first dose step in Part A.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-168h,cagri,2.4/2.4mg,SS area under the cagrilintide concentration-time curve during a dosing interval (0-168 hours) at steady state after last dosing of cagrilintide 2.4 mg in combination with semaglutide 2.4 mg</measure>
    <time_frame>Day 148 (pre-dose) to Day 155 (168 hours post-dose)</time_frame>
    <description>measured in nmol⸱h/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,cagri,2.4/2.4mg,SS maximum concentration of cagrilintide at steady state after last dosing of cagrilintide 2.4 mg in combination with semaglutide 2.4 mg</measure>
    <time_frame>Day 148 (pre-dose) to Day 155 (168 hours post-dose)</time_frame>
    <description>measured in nmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-168h,sema,2.4/2.4mg,SS area under the semaglutide concentration-time curve during a dosing interval (0-168 hours) at steady state after last dosing of semaglutide 2.4 mg in combination with cagrilintide 2.4 mg</measure>
    <time_frame>Day 148 (pre-dose) to Day 155 (168 hours post-dose)</time_frame>
    <description>measured in nmol⸱h/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,sema,2.4/2.4mg,SS maximum concentration of semaglutide at steady state after last dosing of semaglutide 2.4 mg in combination with cagrilintide 2.4 mg</measure>
    <time_frame>Day 148 (pre-dose) to Day 155 (168 hours post-dose)</time_frame>
    <description>measured in nmol/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax,cagri,2.4/2.4mg,SS time since last dosing to maximum concentration of cagrilintide at steady state after last dosing of cagrilintide 2.4 mg in combination with semaglutide 2.4 mg</measure>
    <time_frame>Day 148 (pre-dose) to Day 155 (168 hours post-dose)</time_frame>
    <description>measured in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½,cagri,2.4/2.4mg,SS terminal half-life of cagrilintide at steady state after last dosing of cagrilintide 2.4 mg in combination with semaglutide 2.4 mg</measure>
    <time_frame>Day 148 (pre-dose) to Day 186 (912 hours post-dose)</time_frame>
    <description>measured in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,sema,2.4/2.4mg,SS time since last dosing to maximum concentration of semaglutide at steady state after last dosing of semaglutide 2.4 mg in combination with cagrilintide 2.4 mg</measure>
    <time_frame>Day 148 (pre-dose) to Day 155 (168 hours post-dose)</time_frame>
    <description>measured in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½,sema,2.4/2.4mg,SS terminal half-life of semaglutide at steady state after last dosing of semaglutide 2.4 mg in combination with cagrilintide 2.4 mg</measure>
    <time_frame>Day 148 (pre-dose) to Day 186 (912 hours post-dose)</time_frame>
    <description>measured in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-168h,cagri,1.7/1.7mg,SS area under the cagrilintide concentration-time curve during a dosing interval (0-168 hours) at steady state after last dose of cagrilintide 1.7 mg in combination with semaglutide 1.7 mg</measure>
    <time_frame>Day 120 (pre-dose) to Day 127 (168 hours post-dose)</time_frame>
    <description>measured in nmol⸱h/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-168h,sema,1.7/1.7mg,SS area under the semaglutide concentration-time curve during a dosing interval (0-168 hours) at steady state after last dose of semaglutide 1.7 mg in combination with cagrilintide 1.7 mg</measure>
    <time_frame>Day 120 (pre-dose) to Day 127 (168 hours post-dose)</time_frame>
    <description>measured in nmol⸱h/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART A: Number of treatment emergent adverse events</measure>
    <time_frame>From time of dosing (Day 1) to follow-up (Day 186)</time_frame>
    <description>count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PART B: Number of treatment emergent adverse events</measure>
    <time_frame>From time of dosing (Day 1) to follow-up (Day 29)</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity &amp; Overweight</condition>
  <arm_group>
    <arm_group_label>Part A: Cagrilintide and semaglutide in separate syringes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks treatment with cagrilintide and semaglutide administered as separate injections. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination). Followed by a 38 days follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Cagrilintide and semaglutide combined in DV3384 device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks of treatment with cagrilintide and semaglutide administered using the DV3384 manual syringe. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination. Followed by a 38 days follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cagrilintide and semaglutide combined in DV3384 device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single injection of Cagrilintide 0.25 mg/semaglutide 0.25 mg using the DV3384 manual syringe followed by a 28 days follow-up period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cagrilintide</intervention_name>
    <description>Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks</description>
    <arm_group_label>Part A: Cagrilintide and semaglutide in separate syringes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Once weekly doses of semaglutide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. over 2 weeks</description>
    <arm_group_label>Part A: Cagrilintide and semaglutide in separate syringes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cagrilintide and semaglutide</intervention_name>
    <description>Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe</description>
    <arm_group_label>Part A: Cagrilintide and semaglutide combined in DV3384 device</arm_group_label>
    <arm_group_label>Part B: Cagrilintide and semaglutide combined in DV3384 device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female of non-childbearing potential (NCBP)&#xD;
&#xD;
          -  Aged 18-55 years (both inclusive) at the time of signing informed consent&#xD;
&#xD;
          -  Body mass index (BMI) between 27.0 and 39.9 kg/m^2 (both inclusive) at screening.&#xD;
             Overweight should be due to excess adipose tissue, as judged by the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participation in trial(s) with an amylin analogue unless documented that the&#xD;
             subject was assigned to placebo treatment. Participation is defined as randomisation&#xD;
&#xD;
          -  Any disorder which in the investigator's opinion might jeopardise subject's safety or&#xD;
             compliance with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Søborg</city>
        <zip>2860</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

